Peptides

BPC-157

Evidence: animal_plus_anecdotal

Mechanism of Action

BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.

Dosing Protocol

Standard: Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.

Maintenance: Research indicates 250 mcg once daily for maintenance after initial healing phase.

Administration: subcutaneousintramuscularoral

Timing: Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.

Duration: Typical cycles range from 4-12 weeks depending on the injury being addressed.

Notes

BPC-157 is one of the most widely used healing peptides in the optimization community. The BPC-157 + TB-500 healing stack is considered the gold standard for musculoskeletal recovery. Despite extensive animal data (500+ studies), human clinical data remains extremely limited — a 2025 pilot study demonstrated safety of IV BPC-157 at 10-20 mg doses. Oral BPC-157 is uniquely stable in gastric juice for 24+ hours. The FDA has not approved BPC-157 for any indication.

Stacking

  • TB-500
  • GHK-Cu
  • Pentadeca Arginate (PDA)

Interactions

  • NSAIDs [LOW] — BPC-157 may partially counteract NSAID-induced GI damage; generally complementary.
  • Alcohol [LOW] — Research indicates BPC-157 may offer gastroprotective effects against alcohol-induced damage.
  • Growth Hormone Secretagogues [LOW] — Synergistic healing when combined with GH-elevating peptides.

Contraindications

  • Active cancer or history of cancer (theoretical concern with angiogenesis promotion)
  • Pregnancy and breastfeeding
  • Children under 18

Side Effects

  • Mild nausea (rare)
  • Dizziness (rare)
  • Injection site irritation
  • Headache (uncommon)

Key Papers

  • 10.1016/j.lfs.2018.07.004
  • 10.1038/s41598-020-74022-y
  • 10.1177/15563316251355551

Source Quality

Compounding pharmacy (503A/503B) or research-grade peptide supplier with third-party COA. Arginate salt form preferred for oral use.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should BPC-157 Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds